2022
Benign inheritable disorders of bilirubin metabolism manifested by conjugated hyperbilirubinemia-A narrative review.
Morais MB, Machado MV.
United European Gastroenterol J. 2022 Jul 20. doi: 10.1002/ueg2.12279.
descarregue aqui pdf
Prevalence and Therapeutic Management of Infections by Multi-Drug-Resistant Organisms (MDROs) in Patients with Liver Cirrhosis: A Narrative Review.
Onorato L, Monari C, Capuano S, et al.
Antibiotics (Basel). 2022 Feb 11;11(2):232.
doi: 10.3390/antibiotics11020232.
DESCARREGUE AQUI O PDF
Incidence and prevalence of venous thromboembolism in chronic liver disease: A systematic review and meta-analysis.
Subhani M, Sheth A, Ahmed J, et al.
Thromb Res. 2022 Jul;215:19-29.
doi: 10.1016/j.thromres.2022.05.004.
DESCARREGUE AQUI O PDF
Acute-on-chronic liver failure (ACLF) in 2022: have novel treatment paradigms already arrived?
Abbas N, Rajoriya N, Elsharkawy AM, et al.
Expert Rev Gastroenterol Hepatol. 2022 Jul;16(7):639-652.
doi: 10.1080/17474124.2022.2097070.
DESCARREGUE AQUI O PDF
Position statement on the use of albumin in liver cirrhosis.
Castro-Narro G, Moctezuma-Velázquez C, Male-Velázquez R, et al.
Ann Hepatol. 2022 Jul-Aug;27(4):100708.
doi: 10.1016/j.aohep.2022.100708.
DESCARREGUE AQUI O PDF
Erectile dysfunction in cirrhosis: Its prevalence and risk factors
Yafi FA, Jenkins L, Albersen M, et al.
Nat Rev Dis Primers. 2016 Feb 4;2:16003.
doi: 10.1038/nrdp.2016.3.
DESCARREGUE AQUI O PDF
Non-selective beta-blockers in patients with ascites: The complex interplay among the liver, kidney and heart
Téllez L, Albillos A.
Liver Int. 2022 Apr;42(4):749-761.
doi: 10.1111/liv.15166.
DESCARREGUE AQUI O PDF
Management of Portal Hypertension.
Kulkarni AV, Rabiee A, Mohanty A.
J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1184-1199.
doi: 10.1016/j.jceh.2022.03.002.
DESCARREGUE AQUI O PDF
Advancing Liver Therapeutic Approaches (ALTA) Consortium. North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension.
Boike JR, Thornburg BG, Asrani SK, et al.
Clin Gastroenterol Hepatol. 2022 Aug;20(8):1636-1662.e36.
doi: 10.1016/j.cgh.2021.07.018.
DESCARREGUE AQUI O PDF
Update on the management of gastric varices.
Luo X, Hernández-Gea V.
Liver Int. 2022 Jun;42(6):1250-1258.
doi: 10.1111/liv.15181.
DESCARREGUE AQUI O PDF
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
Reig M, Forner A, Rimola J, et al.
J Hepatol. 2022 Mar;76(3):681-693.
doi: 10.1016/j.jhep.2021.11.018.
DESCARREGUE AQUI O PDF
Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression.
Orci LA, Sanduzzi-Zamparelli M, Caballol B, et al.
Clin Gastroenterol Hepatol. 2022 Feb;20(2):283-292.e10.
doi: 10.1016/j.cgh.2021.05.002.
DESCARREGUE AQUI O PDF
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.
Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, et al.
J Hepatol. 2022 May;76(5):1109-1121.
doi: 10.1016/j.jhep.2021.12.010.
DESCARREGUE AQUI O PDF
AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.
Long MT, Noureddin M, Lim JK.
Gastroenterology. 2022 Jul 13:S0016-5085(22)00628-X.
doi: 10.1053/j.gastro.2022.06.023.
DESCARREGUE AQUI O PDF
Nonalcoholic Fatty Liver Disease and the Gut-Liver Axis: Exploring an Undernutrition Perspective.
Bauer KC, Littlejohn PT, Ayala V, et al.
Gastroenterology. 2022 Jun;162(7):1858-1875.e2.
doi: 10.1053/j.gastro.2022.01.058.
DESCARREGUE AQUI O PDF
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group.
McPherson S, Armstrong MJ, Cobbold JF, et al.
Lancet Gastroenterol Hepatol. 2022 Aug;7(8):755-769.
doi: 10.1016/S2468-1253(22)00061-9.
DESCARREGUE AQUI O PDF
Waist Circumference and Insulin Resistance Are the Most Predictive Metabolic Factors for Steatosis and Fibrosis.
Claypool K, Long MT, Patel CJ.
Clin Gastroenterol Hepatol. 2022 Jun 6:S1542-3565(22)00532-8.
doi: 10.1016/j.cgh.2022.05.021.
DESCARREGUE AQUI O PDF
Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study.
Akuta N, Kawamura Y, Fujiyama S, et al.
Hepatol Commun. 2022 May 17.
doi: 10.1002/hep4.2005.
DESCARREGUE AQUI O PDF
Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder.
Vannier AGL, Shay JES, Fomin V, et al.
JAMA Netw Open. 2022 May 2;5(5):e2213014.
doi: 10.1001/jamanetworkopen.2022.13014.
DESCARREGUE AQUI O PDF
Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis.
Harrington C, Krishnan S, Mack CL, et al.
Hepatology. 2022 May 25.
doi: 10.1002/hep.32591.
DESCARREGUE AQUI O PDF
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
Bowlus CL, Galambos MR, Aspinall RJ, et al.
J Hepatol. 2022 Aug;77(2):353-364.
doi: 10.1016/j.jhep.2022.02.033.
DESCARREGUE AQUI O PDF
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group.
Pape S, Snijders RJALM, Gevers TJG, et al.
J Hepatol. 2022 Apr;76(4):841-849.
doi: 10.1016/j.jhep.2021.12.041.
DESCARREGUE AQUI O PDF
CAQ Corner: Acute liver failure management and liver transplantation.
Pan JJ, Fontana RJ.
Liver Transpl. 2022 May 16.
doi: 10.1002/lt.26503.
DESCARREGUE AQUI O PDF
Immune-checkpoint inhibitors: long-term implications of toxicity.
Johnson DB, Nebhan CA, Moslehi JJ, et al.
Nat Rev Clin Oncol. 2022 Apr;19(4):254-267.
doi: 10.1038/s41571-022-00600-w.
DESCARREGUE AQUI O PDF
Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases.
Ginès P, Castera L, Lammert F, et al..
Hepatology. 2022 Jan;75(1):219-228.
doi: 10.1002/hep.32163.
DESCARREGUE AQUI O PDF
Clinical, histological and molecular profiling of different stages of alcohol-related liver disease.
Ventura-Cots M, Argemi J, Jones PD, et al.
Gut. 2022 Jan 6:gutjnl-2021-324295.
doi: 10.1136/gutjnl-2021-324295.
LINK
Ferroptosis and metabolic dysfunction-associated fatty liver disease: is there a link?
Feng G, Byrne CD, Targher G, et al.
Liver Int. 2022 Jan 10.
doi: 10.1111/liv.15163.
DESCARREGUE AQUI O PDF
Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
Boursier J, Hagström H, Ekstedt M, et al.
J Hepatology. 2022
doi: 0.1016/ j.jhep.2021.12.031.
LINK
Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice.
Desjonqueres E, Campani C, Marra F, et al.
Liver Int. 2022 Jan 4.
doi: 10.1111/liv.15152.
DESCARREGUE AQUI O PDF
Risk of transfusion-transmitted hepatitis E virus infection from pool-tested platelets and plasma.
Cordes AK, Goudeva L, Lütgehetmann M, et al.
J Hepatol. 2022 Jan;76(1):46-52.
doi: 10.1016/j.jhep.2021.08.018.
LINK
Gamma-Glutamyl Transferase (γ-GT) – an old dog with new tricks?
Brennan PN, Dillon JF, Tapper EB.
Liver Int. 2022 Jan;42(1):9-15.
doi: 10.1111/liv.15099.
DESCARREGUE AQUI O PDF
2021
Antibiotic prophylaxis in patients with cirrhosis: Current evidence for clinical practice
Ferrarese A, Passigato N, Cusumano C, et al.
World J Hepatol 2021; 13(8): 840-852.
doi: 10.4254/wjh.v13.i8.840
descarregue aqui o pdf
Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis
Martínez J, Hernández-Gea V, Rodríguez-de-Santiago E, et al.
J Hepatol. 2021 Aug;75(2):342-350.
doi: 10.1016/j.jhep.2021.03.026
descarregue aqui o pdf
Changes in ascitic fluid polymorphonuclear cell counts impact mortality in patients with spontaneous bacterial peritonites
Santana E, Rezende V, Lima GC, et al.
Clin Gastroenterol Hepatol. 2021 Jul 14:S1542-3565(21)00750-3.
doi: 10.1016/j.cgh.2021.07.019
descarregue aqui o pdf
Tuberculosis in cirrhosis- A diagnostic and management conundrum
Mishra, Saurabh et al.
Journal of Clinical and Experimental Hepatology. 2021.
doi: 10.1016/j.jceh.2021.09.003
descarregue aqui o pdf
A Brief History of Hepatic Encephalopathy.
Bass, N.M.
Clinical Liver Disease. 2021;18: 49-62.
Doi: 10.1002/cld.1119
DESCARREGUE AQUI O PDF
2021 ISHEN guidelines on animal models of hepatic encephalopathy
DeMorrow S, Cudalbu C, Davies N, Jayakumar AR, Rose CF.
Liver Int. 2021;41(7):1474-1488.
doi:10.1111/liv.14911
descarregue aqui o pdf
Microbiome Therapeutics for Hepatic Encephalopathy
Bloom P, Tapper EB, Young VB, Lok AS.
J Hepatol. 2021 Aug 25:S0168-8278(21)01998-X.
doi: 10.1016/j.jhep.2021.08.004
descarregue aqui o pdf
Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure
Campello E, Zanetto A, Bulato C, et al.
Liver Int. 2021;(May):1-12.
doi:10.1111/liv.1500
descarregue aqui o pdf
More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC
Zanetto A., Elena C., Bulato C. et al.
Hepatology Communications. 2021.
doi: 10.1002/hep4.1781
descarregue aqui o pdf
Non-malignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus.
Driever EG, von Meijenfeldt FA, Adelmeijer J, et al.
Hepatology. 2021 Sep 24.
doi: 10.1002/hep.32169.
DESCARREGUE AQUI O PDF
Comparison of fondaparinux and low molecular weight heparin in the treatment of portal vein thrombosis in cirrhosis
Senzolo M, Piano S, Shalaby S, et al.
Am J Med. 2021;0(0).
doi:10.1016/J.AMJMED.2021.05.013
link
Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis
Koh JH, Liew ZH, Ng GK, et al.
Dig Liver Dis. 2021.
doi:10.1016/j.dld.2021.07.039
descarregue aqui o pdf
Mistakes in nutrition in chronic liver disease and how to avoid them
Merli M and Lapenna L.
UEG Education 2021; 21: 23–25.
descarregue aqui o pdf
Micronutrient deficiencies in patients with decompensated liver cirrhosis
Llibre-Nieto G, Lira A, Vergara M, et al.
Nutrients. 2021;13(4):1-14.
doi:10.3390/nu13041249
DESCARREGUE AQUI O PDF
Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology.
D’Amico G, Maruzzelli L, Airoldi A, et al.
J Hepatol. 2021 Dec;75(6):1355-1366.
doi: 10.1016/j.jhep.2021.07.018
linK
EASL-CLIF criteria perform better than NACSELD to diagnose and prognosticate ACLF
Li F, Thuluvath PJ.
J Hepatol. Published online 2021.
doi:10.1016/j.jhep.2021.05.033
link
Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis
Juanola A, Graupera I, Elia C, et al.
J Hepatol. 2021 Sep 13:S0168-8278(21)02029-8.
doi: 10.1016/j.jhep.2021.08.031
descarregue aqui o pdf
Granulocyte-Colony Stimulating Factor (G-CSF) to treat acute-on-chronic liver failure, a multicenter randomized trial (GRAFT study)
Engelmann C, Herber A, Franke A, et al.
J Hepatol. Published online 2021.
doi:10.1016/j.jhep.2021.07.033
Link
Developing Priorities for Palliative Care Research in Advanced Liver Disease: A Multidisciplinary Approach
Patel AA, Woodrell C, Ufere NN, et al.
Hepatol Commun. 2021 Sep;5(9):1469-1480.
doi: 10.1002/hep4.1743
descarregue aqui o pdf
Palliative Care Always: Hepatology-Virtual Primary Palliative Care Training for Hepatologists.
DeNofrio JC, Verma M, Kosinski AS, et al.
Hepatol Commun. 2021 Oct 31.
doi: 10.1002/hep4.1849.
DESCARREGUE AQUI O PDF
The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis
Arroyo V, Angeli P, Moreau R, et al.
J Hepatol. 2021;74(3):670-685.
doi:10.1016/j.jhep.2020.11.048
DESCARREGUE AQUI O PDF
End-stage liver disease: Management of hepatorenal syndrome
Mauro E, Garcia-Olveira L, Gadano A.
Liver Int. 2021;41(S1):119-127.
doi:10.1111/liv.14866
DESCARREGUE AQUI O PDF
Diagnosis and Management of Cirrhotic Cardiomyopathy
Kaur H., Premkumar M.
J Clin Exp Hepatol. 2021. ISSN 0973-6883.
doi: 10.1016/j.jceh.2021.08.016
descarregue aqui o pdf
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis.
Pose E, Solà E, Lozano JJ, et al.
Hepatol Commun. 2021 Dec 28.
doi: 10.1002/hep4.1881.
DESCARREGUE AQUI O PDF
Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential
Brown SA, Izzy M, Watt KD.
Hepatology. 2021;73(5):2051-2062.
doi:10.1002/hep.31595
link
Mortality Trends in Chronic Liver Disease and Cirrhosis in the United States, Before and During COVID-19 Pandemic.
Kim D, Bonham CA, Konyn P, et al.
Clin Gastroenterol Hepatol. 2021 Dec;19(12):2664-2666.e2.
doi: 10.1016/j.cgh.2021.07.009.
DESCARREGUE AQUI O PDF
Management of pregnancy in women with cirrhosis.
Rahim MN, Pirani T, Williamson C, et al.
United European Gastroenterol J.
doi: 10.1177/2050640620977034.
DESCARREGUE AQUI O PDF
Risk Prediction Models for Postoperative Decompensation and Infection in Patients With Cirrhosis: A Veterans Affairs Cohort Study
Mahmud N, Fricker Z, Lewis JD, Taddei TH, Goldberg DS, Kaplan DE.
Clin Gastroenterol Hepatol. 2021 Jul 8:S1542-3565(21)00721-7.
doi: 10.1016/j.cgh.2021.06.050. Epub ahead of print.
link
Portal pressure measurement: Have we come full circle?
Bazarbashi AN, Ryou M.
Gastrointest Endosc. 2021 Mar;93(3):573-576.
doi: 10.1016/j.gie.2020.08.007. PMID: 33583516
descarregue aqui o pdf
North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension
Zhou H, Chen R, Wang J, et al.
Clin Gastroenterol Hepatol. 2021 Jul 15:S1542-3565(21)00749-7.
doi:10.1016/j.cgh.2021.07.018
descarregue aqui o pdf
Low Serum Cholinesterase Identifies Patients With Worse Outcome and Increased Mortality After TIPS.
Stockhoff L, Muellner-Bucsics T, Markova AA, et al.
Hepatol Commun. 2021 Sep 28.
doi: 10.1002/hep4.1829.
DESCARREGUE AQUI O PDF
Friend or Foe? Spontaneous Portosystemic Shunts in Cirrhosis-Current Understanding and Future Prospects
Rajesh S, Philips CA, Ahamed R, et al.
Gastroenterol Hepatol. 2021 Aug 12;2021:8795115.
doi: 10.1155/2021/8795115
descarregue aqui o pdf
Outcomes After TIPS for Ascites and Variceal Bleeding in a Contemporary Era—An ALTA Group Study
Boike JR, Mazumder NR, Kolli KP et al.
Am J Gastroenterol. 2021 Jun 23.
doi: 10.14309/ajg.0000000000001357
link
The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis.
Reiberger T.
Hepatol Commun. 2021 Dec 14.
doi: 10.1002/hep4.1855.
DESCARREGUE AQUI O PDF
Diagnostic Criteria and LI-RADS for Hepatocellular Carcinoma
Lee YT, Wang JJ, Zhu Y, Agopian VG, Tseng HR, Yang JD.
Clin Liver Dis (Hoboken). 2021 Aug 5;17(6):409-413.
doi: 10.1002/cld.1075
descarregue aqui o pdf
BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update.
Reig M, Forner A, Rimola J, et al.
J Hepatol. 2021 Nov 18:S0168-8278(21)02223-6.
doi: 10.1016/j.jhep.2021.11.018.
DESCARREGUE AQUI O PDF
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
Greten TF, Abou-Alfa GK, Cheng AL, et al.
J Immunother Cancer. 2021 Sep;9(9):e002794.
doi: 10.1136/jitc-2021-002794
descarregue aqui o pdf
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Pfister D, Núñez NG, Pinyol R, et al.
Nature. 2021 Apr;592(7854):450-456.
doi: 10.1038/s41586-021-03362-0.
DESCARREGUE AQUI O PDF
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score.
Scheiner B, Pomej K, Kirstein MM, et al.
J Hepatol. 2021 Oct 11:S0168-8278(21)02100-0.
doi: 0.1016/j.jhep.2021.09.035
DESCARREGUE AQUI O PDF
Systemic treatment of hepatocellular carcinoma. An EASL position paper
Bruix J, Chan SL, Galle PR, et al.
J Hepatol. 2021 Jul 10:S0168-8278(21)01903-6.
doi:10.1016/j.jhep.2021.07.004
descarregue aqui o pdf
Liver Transplantation Criteria for Hepatocellular Carcinoma, Including Posttransplant Management
Mehta N.
Clin Liver Dis. 2021;17(5):332-336.
doi:10.1002/cld.1054
descarregue aqui o pdf
Safety , Efficacy , and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma : Randomized Expansion of a Phase I / II Study abstract
Kelley RK, Sangro B, Harris W et al.
J Clin Oncol. 2021 Jul 22:JCO2003555.
doi:10.1200/JCO.20.03555
descarregue aqui o pdf
Early diarrhoea under sorafenib as a marker to consider the early migration to second ‐ line drugs
González ÁD, Sapena V, Zamparelli MS, et al.
United European Gastroenterol J. 2021;9(6):655-61.
doi:10.1002/ueg2.12111
DESCARREGUE AQUI O PDF
Down-staging Outcomes for Hepatocellular Carcinoma: Results from the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium
Mehta, N., Frenette, C., Tabrizian, P., et al.
Gastroenterology. 2021;0(0).
doi:10.1053/J.GASTRO.2021.07.033
Link
Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study.
Piratvisuth T, Tanwandee T, Thongsawat S, et al.
Hepatol Commun. 2021 Nov 19.
doi: 10.1002/hep4.1847.
DESCARREGUE AQUI O PDF
Cholangiocarcinoma
Brindley PJ, Bachini M, Ilyas SI, et al.
Nat Rev Dis Primers. 2021 Sep 9;7(1):65.
doi: 10.1038/s41572-021-00300-2
descarregue aqui o pdf
Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?
Gutiérrez-Larrañaga M, González-López E, Roa-Bautista A, et al.
Liver Cancer 2021.
doi: 10.1159/000518104
DESCARREGUE AQUI O PDF
Pre-Transplant Alpha-Fetoprotein > 25.5 and Its Dynamic on Waitlist Are Predictors of HCC Recurrence after Liver Transplantation for Patients Meeting Milan Criteria.
Magro B, Pinelli D, De Giorgio M, et al.
Cancers (Basel). 2021 Nov 27;13(23):5976.
doi: 10.3390/cancers13235976.
DESCARREGUE AQUI O PDF
Viral Hepatitis in Pregnancy: An Update on Screening, Diagnosis, and Management
Sanghi, V. and Lindenmeyer, C.C.
Clinical Liver Disease. 2021. 18: 7-13.
doi: 10.1002/cld.1079
descarregue aqui o pdf
Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B
Bömmel F, Berg T.
Hepatol Commun. 2021;0(0):1-17.
doi:10.1002/hep4.1708
DESCARREGUE AQUI O PDF
Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic
Kaufman HW, Bull-Otterson L, Meyer WA 3rd, et al.
Am J Prev Med. 2021 Sep;61(3):369-376.
doi: 10.1016/j.amepre.2021.03.011
descarregue aqui o pdf
Decreasing VWF-levels upon NSBB-therapy indicate a decreased risk of further decompensation, ACLF, and death
Jachs M, Hartl L, Simbrunner B, et al.
Clin Gastroenterol Hepatol. 2021;(August).
doi:10.1016/j.cgh.2021.07.012
descarregue aqui o pdf
Poor Awareness of Liver Disease Among Adults With NAFLD in the United States
Alqahtani SA, Paik JM, Biswas R, Arshad T, Henry L, Younossi ZM.
Hepatol Commun. 2021;0(0):1-3.
doi:10.1002/hep4.1765
descarregue aqui o pdf
NAFLD Cirrhosis Is Rising Among Childbearing Women and Is the Most Common Cause of Cirrhosis in Pregnancy
Sarkar M, Djerboua M, Flemming JA.
Clin Gastroenterol Hepatol. Published online 2021.
doi:10.1016/j.cgh.2021.01.022
Link
Maternal obesity increases the risk and severity of NAFLD in offspring
Hannes Sharma HB, Panigrahi S, Sarmah AK, Dubey BK.
J Hepatol. 2021 Jul 10:S0168-8278(21)01899-7.
doi:10.1016/j.jhep.2021.06.045
descarregue aqui o pdf
Non-alcoholic fatty liver disease: A patient guideline
Francque S, Marchesini G, Kautz A, et al.
JHEP Reports. 2021.
doi: 10.1016/j.jhepr.2021.100322
descarregue aqui o pdf
Imaging biomarkers of NAFLD, NASH, and fibrosis
Ajmera V, Loomba R.
Mol Metab. 2021;50(January):1-7.
doi:10.1016/j.molmet.2021.101167
descarregue aqui o pdf
Magnetic resonance elastography for the clinical risk assessment of fibrosis, cirrhosis, and portal hypertension in patients with NAFLD
Natarajan Y., Loomba R.
J Clin Exp Hepatol. 2021 Aug.
Doi: 10.1016/j.jceh.2021.08.002
descarregue aqui o pdf
Predicting Liver-Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests.
Johnson AL, Hayward KL, Patel P, et al.
Hepatol Commun. 2021 Nov 15.
doi: 10.1002/hep4.1852.
DESCARREGUE AQUI O PDF
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.
Kanwal F, Shubrook JH, Adams LA, et al.
Gastroenterology. 2021 Nov;161(5):1657-1669.
doi: 10.1053/j.gastro.2021.07.049.
DESCARREGUE AQUI O PDF
Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD
Oh S, Tsujimoto T, Kim B, et al.
JHEP Reports. 2021;3(3):100253.
doi:10.1016/j.jhepr.2021.100253
descarregue aqui o pdf
Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis
Ratziu V.
Clinical Liver Disease. 2021;17(6):398-400.
doi:10.1002/cld.1076
descarregue aqui o pdf
Rational HCC screening approaches for patients with NAFLD.
Singal AG, El-Serag HB.
J Hepatol. 2022 Jan;76(1):195-201.
doi: 10.1016/j.jhep.2021.08.028.
DESCARREGUE AQUI O PDF
Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study
Rumgay H, Shield K, Hadrien Charvat, et al.
Lancet Oncol. 2021 Jul 13:S1470-2045(21)00279-5.
doi:10.1016/S1470-2045(21)00279-5
descarregue aqui o pdf
Effect of Increased Alcohol Consumption During COVID-19 Pandemic on Alcohol-related Liver Disease: A Modeling Study.
Julien J, Ayer T, Tapper EB, et al.
Hepatol Commun. 2021 Dec 14.
doi: 10.1002/hep.32272.
DESCARREGUE AQUI O PDF
Simultaneous Metabolic and Alcohol-associated Fatty Liver Disease (SMAFLD) and Simultaneous Metabolic and Alcohol-associated Steatohepatitis (SMASH)
Senussi NH, McCarthy DM.
Ann Hepatol. 2021 Sep-Oct;24:100526.
doi: 10.1016/j.aohep.2021.100526
descarregue aqui o pdf
Diagnosis and Treatment of Alcohol-Associated Liver Disease: A Review
Singal AK, Mathurin P.
JAMA. 2021;326(2):165–176.
doi:10.1001/jama.2021.7683
link
Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study
Arab JP, Díaz LA, Baeza N et al.
J Hepatol. 2021 Jun 21:S0168-8278(21)00439-6.
doi: 10.1016/j.jhep.2021.06.019
descarregue aqui o pdf
Evaluation of Early vs Standard Liver Transplant for Alcohol-Associated Liver Disease
Herrick-Reynolds, K. M., Punchhi, G., Greenberg, R. S., et al.
JAMA Surg. Published online August 11, 2021.
doi:10.1001/JAMASURG.2021.3748
Link
Alcohol and Acute-on-Chronic Liver Failure
Ballester MP, Sittner R, Jalan R.
Journal of Clinical and Experimental Hepatology, 2021. ISSN 0973-6883.
Doi: 10.1016/j.jceh.2021.12.010.
LINK
Liver biopsy in patients with alcohol-associated liver disease with acute on chronicliver failure
Jophlin L, Singal A.K.
Journal of Clinical and Experimental Hepatology. 2021, ISSN 0973-6883.
doi:10.1016/j.jceh.2021.08.009
descarregue aqui o pdf
Joining the Fight: Enhancing Alcohol Treatment Education in Hepatology.
Winters AC, Aby ES, Fix OK, et al.
Clin Liver Dis (Hoboken). 2021 Nov 20;18(5):225-229.
doi: 10.1002/cld.1127.
DESCARREGUE AQUI O PDF
Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis.
Burghart L, Halilbasic E, Schwabl P, et al.
J Gastroenterol. 2021 Dec 11.
doi: 10.1007/s00535-021-01839-3
DESCARREGUE AQUI O PDF
Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study
Reig A, Álvarez-Navascués C, Vergara M et al.
Am J Gastroenterol. 2021 Jun 23.
doi: 10.14309/ajg.0000000000001343
link
Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis
Vuppalanchi R, Caldwell SH, Pyrsopoulos N, et al.
J Hepatol. 2021 Sep 3:S0168-8278(21)02023-7.
doi: 10.1016/j.jhep.2021.08.025
link
Emerging drugs for the treatment of primary sclerosing cholangitis.
Abbas N, Quraishi MN, Trivedi P
ScienceDirect Pharmacology Curr Opin Pharmacol. 2021 Dec 8;62:23-35.
doi: 10.1016/j.coph.2021.11.003.
LINK
Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis
Laschtowitz A, Zachou K, Lygoura V, et al.
JHEP Reports. 2021;3(4):100321.
doi:10.1016/j.jhepr.2021.100321
descarregue aqui o pdf
Autoimmune hepatitis in patients aged 70 years or older: Disease characteristics, treatment response and outcome
Dalekos GN, Azariadis K, Lygoura V, et al.
Liver Int. 2021;41(7):1592-1599.
doi:10.1111/LIV.14900
link
Hepatic Manifestations of Immunoglobulin G4-Related Disease
Sharzehi, K.
Clinical Liver Disease. 2021.
doi: 10.1002/cld.1087
descarregue aqui o pdf
Wilson’s disease: Revisiting an old friend
Lucena-Valera A, Perez-Palacios D, Muñoz-Hernandez R, et al.
World J Hepatol. 2021 Jun 27;13(6):634-649.
doi: 10.4254/wjh.v13.i6.634
descarregue aqui o pdf
Direct Measurement of ATP7B Peptides Is Highly Effective in the Diagnosis of Wilson Disease
Collins CJ, Yi F, Dayuha R, et al.
Gastroenterology. 2021;160(7):2367-2382.e1.
doi:10.1053/j.gastro.2021.02.052
descarregue aqui o pdf
Hemochromatosis classification: update and recommendations by the BIOIRON Society.
Girelli D, Busti F, Brissot P, Cabantchik I, Muckenthaler MU, Porto G. Blood. 2021 Oct 3:blood.2021011338.
doi: 10.1182/blood.2021011338.
DESCARREGUE AQUI O PDF
Appropriate Clinical Genetic Testing of Hemochromatosis Type 2-4, Including Ferroportin Disease
Kowdley DS, Kowdley KV.
Appl Clin Genet. 2021 Aug 12;14:353-361.
doi: 10.2147/TACG.S269622
descarregue aqui o pdf
Alpha-1 antitrypsin deficiency: a re-surfacing adult liver disorder.
Fromme M, Schneider CV, Trautwein C, Brunetti-Pierri N, Strnad P J Hepatol. 2021 Nov 27:S0168-8278(21)02227-3.
doi: 10.1016/j.jhep.2021.11.022.
DESCARREGUE AQUI O PDF
Genetic Disorders of Bile Acid Transport
Henkel AS.
Clin Liver Dis. 2021;0(0):1-6.
doi:10.1002/cld.1132
descarregue aqui o pdf
Estrogens in Polycystic Liver Disease: A Target for Future Therapies?
Aapkes SE, Bernts LHP, Barten TRM, et al.
Liver Int 2021.
doi:10.1111/liv.14986
DESCARREGUE AQUI O PDF
Palliative Care Always: Hepatology-Virtual Primary Palliative Care Training for Hepatologists.
DeNofrio JC, Verma M, Kosinski AS, et al.
Hepatol Commun. 2021 Oct 31.
doi: 10.1002/hep4.1849.
DESCARREGUE AQUI O PDF
Hepatic Manifestations of Urea Cycle Disorders
Strong, A., Gold, J., Gold, N.B., Yudkoff, M.
Clinical Liver Disease. 2021.
doi: 10.1002/cld.1115
descarregue aqui o pdf
Abnormal liver enzymes: A review for clinicians.
Kalas MA, Chavez L, Leon M, et al.
World J Hepatol. 2021 Nov 27;13(11):1688-1698.
doi: 10.4254/wjh.v13.i11.1688.
DESCARREGUE AQUI O PDF
COVID‐19 ‐Related Downscaling of In‐Hospital Liver Care Decreased Patient Satisfaction and Increased Liver‐Related Mortality
Hartl L, Semmler G, Hofer BS, et al.
Hepatol Commun. 2021;0(0):1-16.
doi:10.1002/hep4.1758
descarregue aqui o pdf
Hepatic Venous Outflow Tract Obstruction: Causes, Natural History, and Treatment.
Gamanagatti, S. and Hemachandran, N.
Clinical Liver Disease. 2021; 18: 117-121.
Doi: 10.1002/cld.1126
LINK
Liver abscess: Complications and Treatment
Sharma S, Ahuja V.
Clinical Liver Disease 2021;0(0):1-5.
doi:10.1002/cld.1128
descarregue aqui o pdf
Clinical management of patients with drug‐induced liver injury (DILI)
Björnsson ES.
United Eur Gastroenterol J. 2021;(March):1-6.
doi:10.1002/ueg2.12113
DESCARREGUE AQUI O PDF
When and how to use direct oral anticoagulants in patients with advanced chronic liver disease?
Maria C De, Galante A, Fasoli A, Gottardi A De.
ScienceDirect Pharmacology Curr Opin Pharmacol. 2021;60:111-116.
doi:10.1016/j.coph.2021.07.006
link
Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors
Turon F, Driever EG, Baiges A, et al.
J Hepatol. Published online 2021.
doi:10.1016/j.jhep.2021.07.020
link
2020
Socioeconomic Inequalities in the Incidence of Alcohol-Related Liver Disease: a Nationwide Danish Study
Askgaard G, Fleming K, Kraglund F, et al.
Hepatology. 2020;72(1):191A-192A.
doi:10.1016/j.lanepe.2021.10017
descarregue aqui o pdf
History of Hepatic Encephalopathy is Not a Contraindication to TIPS Placement for Refractory Ascites
Saab S, Zhao M, Asokan I, Yum JJ, Lee EW.
SSRN Electron J. Published online 2020:1-9.
doi:10.2139/ssrn.3702918
descarregue aqui o pdf
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
Pinato DJ, Kaseb A, Wang Y, et al.
J Immunother Cancer. 2020 Oct;8(2):e000726.
doi: 10.1136/jitc-2020-000726
descarregue aqui o pdf
Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey’s discriminant function <32
Degré D, Stauber RE, Englebert G, et al.
J Hepatol. 2020;72(4):636-642.
doi:10.1016/j.jhep.2019.12.023
descarregue aqui o pdf
Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease
Wooddell CI, Blomenkamp K, Peterson RM, et al.
JCI Insight. 2020;5(12):1-19.
doi:10.1172/jci.insight.135348
descarregue aqui o pdf
Impact of liver test abnormalities and chronic liver disease on the clinical outcomes of patients hospitalized with covid-19
Garrido M, Guedes TP, Silva JA, et al.
GE Port J Gastroenterol. 2021;28(4):253-264.
doi:10.1159/000513593
descarregue aqui pdf
Noninvasive Detection of Clinically Significant Portal Hypertension in Compensated Advanced Chronic Liver Disease
Vuille-Lessard É, Rodrigues SG, Berzigotti A.
Clin Liver Dis. 2021;25(2):253-289.
doi:10.1016/j.cld.2021.01.005
descarregue aqui pdf
Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease
Pons M, Augustin S, Scheiner B, et al.
Am J Gastroenterol. 2021;116(4):723-732.
doi:10.14309/ajg.0000000000000994
LINK
A single cell gene expression atlas of 28 human livers
Brancale J, Vilarinho S.
J Hepatol. Published online 2021.
doi:10.1016/j.jhep.2021.03.005
descarregue aqui o pdf
Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease
Cortez‐Pinto H, Liberal R, Lopes S, et al.
United Eur Gastroenterol J. 2021;(March):1-8.
doi:10.1002/ueg2.12095
descarregue aqui o pdf
Established and novel therapeutic options for autoimmune hepatitis
Liberal R, de Boer YS, Heneghan MA.
Lancet Gastroenterol Hepatol. 2021;6(4):315-326.
doi:10.1016/S2468-1253(20)30328-9
LINK
Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease
Lackner C, Stauber RE, Davies S, et al.
J Hepatol. Published online 2021.
doi:10.1016/j.jhep.2021.05.029
LINK
Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality
Costa D, Simbrunner B, Jachs M, et al.
J Hepatol. 2021;74(4):819-828.
doi:10.1016/j.jhep.2020.10.004
descarregue aqui o pdf
Determinants of mortality in patients with cirrhosis and uncontrolled variceal bleeding
Kumar R, Kerbert AJC, Sheikh MF, et al.
J Hepatol. 2021;74(1):66-79.
doi:10.1016/j.jhep.2020.06.010
LINK
Burden of Liver Cirrhosis in Portugal between 2010 and 2017
Silva JM, Silva MJ, Calinas F, Nogueira PJ.
GE Port J Gastroenterol. 2021;28(3):153-161.
doi:10.1159/000510729
descarregue aqui o pdf
Optic Nerve Sheath Diameter in Acute Liver Failure: A Prospective Cohort Study
Cardoso FS, Pereira R, Moreno R, et al.
GE Port J Gastroenterol. 2021;28(3):170-178.
doi:10.1159/000511646
descarregue aqui o pdf
Long-Term Follow-Up of a Portuguese Single-Centre Cohort of Persons with Haemophilia and Hepatitis C Virus Infection
Pereira Guedes T, Garrido M, Kuttner Magalhães R, et al.
GE Port J Gastroenterol. 2021;28(2):79-86.
doi:10.1159/000510023
descarregue aqui o pdf
2020
Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and meta-analysis
Mendoza YP, Rodrigues SG, Bosch J, Berzigotti A.
Dig Liver Dis. 2020;52(9):958-965.
doi:10.1016/j.dld.2020.06.048
LINK
Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complication
Will V, Rodrigues SG, Stirnimann G, et al.
United Eur Gastroenterol J. 2020;8(8):961-969.
doi:10.1177/2050640620938525
descarregue aqui o pdf
Beta-blockers in cirrhosis: Evidence-based indications and limitations
Rodrigues SG, Mendoza YP, Bosch J.
JHEP Reports. 2020;2(1):100063.
doi:10.1016/j.jhepr.2019.12.001
descarregue aqui o pdf
The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology
Trebicka J, Fernandez J, Papp M, et al.
J Hepatol. 2020;73(4):842-854.
doi:10.1016/j.jhep.2020.06.013
descarregue aqui o pdf
Elimination of Hepatitis C in Portugal: An Urban Legend?
Velosa J, Macedo G.
GE Port J Gastroenterol. 2020;27(3):166-171.
doi:10.1159/000505582
descarregue aqui o pdf
Long-Term Follow-Up of Advanced Liver Disease after Sustained Virological Response to Treatment of Hepatitis C with Direct-Acting Antivirals: Outcomes from a Real-World Portuguese Cohort
Guedes TP, Fragoso P, Lemos C, et al.
GE Port J Gastroenterol. 2020;27(3):149-159.
doi:10.1159/000503074
descarregue aqui o pdf
Secondary Sclerosing Cholangitis in Critically Ill Patients: An Underdiagnosed Entity
Martins P, Verdelho Machado M.
GE Port J Gastroenterol. 2020;27(2):103-114.
doi:10.1159/000501405
descarregue aqui o pdf
Palliative Care in End-Stage Liver Disease Patients Awaiting Liver Transplantation: Review
Silva SV, Freire E, Pessegueiro Miranda H.
GE Port J Gastroenterol. 2020;27(6):417-428.
doi:10.1159/000507336
descarregue aqui o pdf
Retrospective Study of Transjugular Intrahepatic Portosystemic Shunt Placement for Cirrhotic Portal Hypertension
Santos S, Dantas E, Veloso Gomes F, et al.
GE Port J Gastroenterol. 2020;28(1):5-12.
doi:10.1159/000507894
descarregue aqui o pdf
